order over six consecutive attacks, 66 patients with episodic migraine received either
placebo or Maxalt (10-mg rizatriptan) under three information conditions (told placebo, told Maxalt or placebo, told
Maxalt ... initial no-treatment attack, yielding a total of 459 documented migraine
attacks. Maxalt was superior to placebo for pain relief. Increasing information from negative to neutral to positive
progressively enhanced ... effects of both placebo and Maxalt. The efficacy of open-label placebo was superior to
that of no treatment. Relative to no treatment, the placebo, under each information condition, accounted